Replies to post #11172 on PharmaRoth Labs, Inc. (ROTH)

[old biohf guy]

You say "None of the previous post is accurate", but quite to the contrary, sweetlou's post #11171 is 100% accurate.

[sweetlou]

You falsely stated that “none of my previous post was accurate”, yet reference to the studies was contained in my post itself and any interested investors can verify from source information. I encourage anyone to post information showing my statements to be inaccurate if you can. My goal is to communicate accurate information on the company and product and offer opinions on the significance of that information.
My post is included below for information:


Beware of ANY information unless it is able to be publicly verified. Any information in my posts comes from readily verifiable information which I encourage any to check. In fact I encourage checking the track record of false information indicating insolvency and extreme warnings about nonexistent stops on trading as but a small cross section of examples.

Here is what we know about Sucanon so far in advance of the trial at ABC hospital in Mexico City for which we are awaiting results...
The summaries of studies below come from publicly verifiable information on previous Sucanon studies, which the FDA referred to as "substantial clinical investigations"

Preclinical in vitro tests of Sucanon (then diab2) in rat muscle showed an up regulation of insulin receptors
Sucanon outperformed biguanides (Metformin) and sulfonylureas (Glucotrol, Micronase, Amaryl) in rat models
Pharmacokinetics showed dose response relationship, peak response 2-4 hours, no effect by 10 hours
Toxicity: none at dosing 2000x therapeutic levels in dogs and rats with therapeutic index > 10,000, no carcinogenicity, teratogenicity, or mutagenicity in mice
Clinical studies: randomized double blind placebo controlled study in 370 adult type 2 diabetics, 6 months (1 month screening, 4 months treatment, 1 month post treatment) Sucanon outperformed Glyburide in control of fasting blood sugar levels, urinary glucose excretion, and glucose tolerance testing
(All above results done under management of Bob Rieveley, Biotech holdings, before involvement of FROI or ROTH current individuals)

Finally Dr Rojas study presented at EASD annual meeting 2013 in Barcelona Spain: 97 pre diabetic adult patients (HbA1C 5.7 to 6.2) 12 weeks with normalization of HbA1C (below 5.7) in 81% of study population and decrease in weight and visceral body fat, in contrast to weight gain commonly seen with alternative oral diabetes medications